N early half of all heart failure patients present with normal or near normal systolic left ventricular (LV) function. 1 This condition has been labeled heart failure with preserved ejection fraction (HFpEF). 2 The pathophysiology underlying HFpEF is complex and still incompletely understood. Expansion of the extracellular volume (ECV) due to accumulation of extracellular matrix in the interstitial myocardial space is thought to be one of the main pathophysiologic mechanisms underlying LV stiffening in HFpEF. 3, 4 Despite the central role of ECV in this condition, data on its prognostic relevance are limited. 5 The gold standard for ECV quantification relies on the histological analysis of endomyocardial biopsies retrieved from the LV. This method, however, is invasive and carries significant risks. Our group previously showed that myocardial postcontrast T1 time by cardiac magnetic resonance (CMR) imaging is significantly associated with prognosis and correlates with ECV by histology. 5 However, more recently, CMR T1 mapping, using the modified Look-Locker inversion recovery (MOLLI) sequence, has been proposed as the more robust technique, independent of potential confounders such as renal function, heart rate, or time of acquisition. [6] [7] [8] [9] [10] However, the diagnostic and prognostic power of ECV as measured by the MOLLI technique in HFpEF is unknown.
Outcome Measures
All patients underwent CMR imaging at baseline, including T1 mapping by the MOLLI sequence. Patients were prospectively followed by ambulatory visits and telephone calls at 6-month intervals. The main outcome measure was a combined end point consisting of hospitalization for heart failure or death from cardiovascular causes. End points were ascertained by follow-up visits and phone calls and adjudicated by our internal adjudication committee consisting of D.B. and J.M., who were blinded to CMR results and other patient characteristics.
Assessment Techniques Transthoracic Echocardiography With Tissue Doppler Analysis
All transthoracic echocardiography studies were performed by board certified physicians using scanners such as GE Vivid 7 and Vivid S70 (GE Healthcare, Wauwatosa, WI). LV ejection fraction and mitral venous flow Doppler measures were assessed according to the standard techniques. 15
Right and Left Heart Catheterization
For right heart catheterization, a 7F Swan-Ganz catheter (Baxter, Irvine, CA) was inserted via a jugular or femoral access. Filling pressures were averaged after recording of 8 heart cycles using CathCorLX (Siemens AG, Berlin and Munich, Germany). Pulmonary artery wedge pressure, pulmonary arterial pressure, cardiac output, right atrial pressure, arterial oxygen saturation, and mixed venous oxygen saturation were determined. Cardiac output was measured by both thermodilution and Fick method. Simultaneously, all patients underwent direct assessment of LV filling pressures, followed by coronary angiography. Derived hemodynamic parameters were calculated according to standard formulae.
CMR Imaging
CMR examinations were performed on a 1.5-T scanner (MAG-NETOM Avanto; Siemens Healthcare GmbH, Erlangen, Germany), which consisted of standard protocols that included late gadolinium enhancement imaging (0.1 mmol/kg gadobutrol [Gadovist; Bayer Vital GmbH, Leverkusen, Germany]) if estimated glomerular filtration rate was ≥30 mL/min/1.73m2 (2 Prime). 16 Blood was drawn at the time of insertion of the intravenous cannula for hematocrit and serum creatinine measurement. Late gadolinium enhancement was quantified on short-axis stacks using a semiautomatic approach by defining a threshold of 5 standard deviations (SD) above mean signal intensity of healthy myocardium. 17 Electrocardiographically triggered MOLLI using a 5(3)3 prototype (5 acquisition heartbeats followed by 3 recovery heartbeats and further 3 acquisition heartbeats) was applied for precontrast T1 mapping. This method generates an inline, pixel-based T1 map by acquiring a series of images over several heartbeats with shifted T1 times, inline motion correction, and inline calculation of the T1 relaxation curve within 1 breath hold. T1 sequence parameters were as follows: starting inversion time 120 ms, inversion time increment 80 ms, reconstructed matrix size 256×218, and measured matrix size 256×144 (phase-encoding resolution 66% and phase-encoding field of view 85%). T1 maps were created both before and 15 minutes after contrast agent application. For postcontrast T1 mapping, a 4(1)3(1)2 prototype was used. T1 values from a midcavity short-axis slice and a midcavity 4-chamber view were averaged. T1 values of the blood pool were derived with sufficient distance to papillary muscles and the endomyocardial border. Areas of focal fibrosis identified by late gadolinium enhancement were excluded ( Figure 1 ).
The following formula was used for ECV calculation: 18 T1 myo pre/T1 blood pre indicates myocardial/blood native T1 times and T1 myo post/T1 blood post indicates T1 times of myocardium/blood 15 minutes after gadobutrol application.
The local reference range for normal MOLLI-ECV values is 25.4±2.7%, derived from 36 healthy sex-matched controls.
Myocardial Biopsy and Histological Analysis
Biopsies were taken from the LV free wall during left heart catheterization using dedicated devices (Bipal biopsy forceps; Cordis Corporation, Bridgewater, NJ). Specimens were embedded in paraffin, stained with Modified Trichrome as previously described 19 and were scanned at 20-folded magnification using a high-resolution microscope and TissueFAXS software (TissueGnostics, Vienna, Austria, Figure 2A ). ECV by this method (Histo-ECV) was quantified with ImageJ software using a color-threshold macro based on an algorithm by G. Landini. Endocardium, blood vessels, and perivascular tissue were excluded from the analysis ( Figure 2B ). 
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Statistical Analysis
Continuous variables are expressed as mean±SD or as median and interquartile ranges. Categorical variables are presented as numbers and percent. Continuous and categorical variables were compared using the Mann-Whitney U test and χ 2 test as appropriate. Separate univariable Cox regression models were performed for clinical, CMR, and invasive hemodynamic parameters, followed by a multiple Cox regression model with stepwise forward selection to assess the effect of the respective parameters on event-free survival. The significance level for a predictor to enter the model was 0.05, and the limit to stay in the model was 0.1. In a final step, all parameters associated with outcome within the respective group were entered into an additional combined multivariable model. Kaplan-Meier analysis (log-rank test) was applied to verify the time-dependent discriminative power of ECV. Spearman correlation coefficients were used to report the relationship between CMR and histological findings. By Bland-Altman analysis, agreement between MOLLI-ECV and Histo-ECV was assessed and reported as mean difference and corresponding 95% limits of agreement (±1.96 SD). For all tests, the significance level was set to P≤0.05. IBM SPSS version 21 (SPSS Inc, Chicago, IL) was used for statistical analyses.
Results
Baseline Characteristics
Between July 2012 and December 2015, 197 HFpEF patients were enrolled of whom 80 patients had to be excluded from the analysis. Reasons for exclusion are displayed in Figure 3 . The remaining 117 patients were stratified according to the median MOLLI-ECV, which was 28.9%. Baseline characteristics of patients with MOLLI-ECV ≥28.9% and <28.9% were compared ( Table 1 ; Table I in the Data Supplement for echocardiographic data).
Cardiac Outcomes
After baseline evaluation, patients were followed for a median of 24.0 months (interquartile range, 6.0-32.0 months). During follow-up, 34 patients reached the combined end point. Four patients died, and 30 patients were hospitalized due to heart failure. Three noncardiac deaths were observed (pancreatic cancer, pneumonia, and glioblastoma). Table II in the Data Supplement shows baseline characteristics with respect to outcome. 
Parameters Associated With Outcome
For Kaplan-Meier analysis, patients were stratified according to the median MOLLI-ECV (28.9%; Figure 4 ). Patients with higher MOLLI-ECV had shorter event-free survival (log-rank test: P=0.028). Table 2 shows the results of the univariable and multivariable Cox regression analysis. Among clinical parameters, estimated glomerular filtration rate (P=0.049) and serum NT-proBNP (P=0.002) were associated with outcome. Among CMR parameters, MOLLI-ECV (P=0.038) and right ventricular end-diastolic volume (P=0.008), and among invasive hemodynamic variables, pulmonary vascular resistance (P<0.001), remained associated with eventfree survival.
When all variables (clinical, imaging, and hemodynamics), which were associated with adverse outcome in the multivariable Cox models, were included in a combined Cox model, right ventricular end-diastolic volume (P<0.001) and pulmonary vascular resistance (P=0.002), but not MOLLI-ECV (P=0.978), remained associated with outcome ( Table 3 ).
Correlation of MOLLI-ECV With Variables Related to Signs and Symptoms of Heart Failure
MOLLI-ECV was significantly correlated with serum NT-proBNP (R=0.369; P<0.001; Figure IA 
Histopathologic Analysis
Histological samples were obtained from 18 HFpEF patients. A representative specimen is shown in Figure 2 . No late gadolinium enhancement was present in the LV free wall where biopsies were taken. MOLLI-ECV showed good correlation with Histo-ECV (R=0.494; P=0.037; Figure 5A ). Bland-Altman analysis ( Figure 5B ) showed good agreement between histologically measured ECV and MOLLI-ECV (mean difference, 0.8%; limits of agreement, −7.0% and 8.6% 
Discussion
This study adds to the existing evidence by showing an important pathophysiologic and prognostic role of extracellular matrix accumulation in HFpEF. In a prospective cohort of 117 HFpEF patients, ECV by the CMR MOLLI sequence was significantly correlated with the histological amount of extracellular matrix in LV biopsy samples and variables linked to signs and symptoms of heart failure and was also associated with event-free survival.
HFpEF is a heterogeneous disease, with risk factors including female sex, advanced age, hypertension, diabetes mellitus, and obesity. 20 The underlying mechanisms that cause HFpEF are not fully understood, but affected patients face a poor prognosis. 21 LV diastolic dysfunction because of extracellular matrix accumulation 3 is regarded as one of the main pathophysiologic abnormalities. 2, 22, 23 In support of this, we detected a significant correlation of MOLLI-ECV with echocardiographic E/A ratio. Furthermore, MOLLI-ECV of HFpEF patients was significantly higher than MOLLI-ECV of 36 healthy sex-matched controls (29.3±3.9% versus 25.4±2.7%; P<0.001). The heterogeneous nature of HFpEF poses a challenge for the development of treatments, and no specific therapy has yet demonstrated a convincing reduction in morbidity or mortality in affected individuals. 2 Measurement of ECV by CMR T1 mapping has the potential to become a prognostic marker in HFpEF and also a monitoring tool for the assessment of new therapeutic agents. 24
Prognostic Relevance of T1 Mapping Using the MOLLI Sequence in HFpEF
Only few studies have investigated the prognostic impact of MOLLI-ECV. 6, 10, [25] [26] [27] [28] In the present study, MOLLI-ECV was associated with adverse outcome among CMR parameters but failed to reach statistical significance in the combined multivariable model that also included clinical and hemodynamic parameters (Tables 2 and 3 ). This result is in line with previous COPD indicates chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; LA, left atrial; LV, left ventricular; MOLLI-ECV, modified Look-Locker inversion recovery sequence derived extracellular volume; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; NYHA, New York Heart Association; RA, right atrial; RV, right ventricular; SaO 2 , arterial oxygen saturation; and SvO 2 , mixed venous oxygen saturation.
*NT-proBNP was graded into quintiles for this analysis. †Per 30 m increase. ECV by CMR T1 Mapping in HFpEF findings from our group in a larger cohort of patients with various cardiac diseases. 6 In contrast, several recent studies have identified MOLLI-ECV as a predictor of outcome among clinical and imaging parameters. 10, [26] [27] [28] However, these differing results have previously been discussed and have been attributed to the inclusion of particularly important variables in our analysis, such as NT-proBNP, renal function, atrial fibrillation, and right ventricular size and function. 6 These variables were not included in the statistical models used in the aforementioned studies. 10, [26] [27] [28] Puntmann et al 28 recently identified native T1 times but not ECV as a predictor of outcome in a large cohort of patients with nonischemic dilated cardiomyopathy (n=637). In our patients, however, native T1 times were not associated with adverse outcome. This conflicting result appears most likely due to differences in disease entities.
Correlation of Extracellular Matrix Accumulation With Variables Related to Signs and Symptoms of HFpEF
In line with recent publications, [29] [30] [31] [32] several parameters were associated with adverse outcome, such as pulmonary arterial pressures, serum NT-proBNP levels, severity of symptoms, and parameters of right ventricular dysfunction. We observed significant correlations of MOLLI-ECV with these clinically important parameters. Therefore, a therapeutic modulation of ECV in HFpEF might have the potential to decrease cardiac filling pressures, improve symptomatic status, increase exercise capacity, and improve outcomes.
Histological Validation
Several studies 5, 7, 8, [33] [34] [35] [36] [37] [38] have validated ECV by CMR T1 mapping against myocardial biopsies, but not in HFpEF patients.
In the present study, the amount of extracellular matrix in biopsies from 18 HFpEF patients was significantly correlated with MOLLI-ECV, which in turn was related with outcome.
Limitations
Due to the single-center setting of our study, a center-specific bias cannot be excluded. However, limiting data collection to 1 center brings several advantages: (1) adherence to a constant clinical routine, (2) constant quality of work-up, and (3) constant follow-up.
Because of the small size of myocardial biopsy specimens that can be retrieved during left heart catheterization, the amount of extracellular matrix in these samples may not necessarily reflect ECV expansion within the entire myocardium. Despite this potential shortcoming, good agreement was found between MOLLI-ECV and extracellular matrix expansion in myocardial biopsies.
MOLLI-ECV was associated with event-free survival only among CMR imaging variables but was not significantly associated with outcome when clinical and hemodynamic variables were entered into the model. This result is in line with a previous study in a larger patient cohort with various cardiac diseases. 6 No other HFpEF outcome study to date assessed MOLLI-ECV in conjunction with all the variables included here.
Conclusions
Our study demonstrates that MOLLI-ECV in HFpEF accurately reflects histological ECV, correlates with markers of disease severity, and is associated with outcome among CMR parameters but not after adjustment for important clinical and invasive hemodynamic parameters. MOLLI-ECV will establish its role as a monitoring tool aiding in the development of new therapeutic agents and has the potential of becoming an important prognostic marker in HFpEF.
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